Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

real world study

28th Oct 2025

Plain language summary of POLARIS: real-world palbociclib effectiveness and life quality impact

Screenshot of a summary article on palbociclib treatment for advanced/metastatic breast cancer in older patients, with key findings, how-to guide for downloading, and publication details.
19th Sep 2025

Plain language summary looking at palbociclib treatment for advanced breast cancer in older patients

27th May 2025

How tafamidis affects lifespan in people with transthyretin amyloid heart disease: plain language summary

13th May 2025

Real-world survival rates for advanced prostate cancer patients using abiraterone or enzalutamide treatments: a plain language summary

This summary is about a study that was published in the medical journal The Oncologist in July 2023. The combination of palbociclib with an aromatase inhibitor (AI) was approved by the FDA in 2015 as a treatment for people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer(MBC). However, the effectiveness of palbociclib in African–Americans with MBC is not well studied. The goal of this study was to find out whether adding palbociclib to an AI helped African–Americans with HR+/HER2− MBC live longer.
30th Apr 2024

A plain language summary looking at the palbociclib/aromatase inhibitor treatment combination in African-Americans with metastatic breast cancer (MBC)

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy